Edmond de Rothschild Investment Partners investiert in Allecra Therapeutics
Edmond de Rothschild Investment Partners co-leads the €15 Million Series A financing of Allecra Therapeutics with its new fund BioDiscovery 4
Edmond de Rothschild Investment Partners announces the first investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences, through its participation in the Series A financing round of Allecra Therapeutics, which it co-leads with Forbion Capital Partners. EMBL Ventures is also part of the syndicate.
Allecra was formed in 2013 in France and Germany, as a strategic partnership between Orchid Chemicals & Pharmaceuticals Limited (Chennai, India), the founders – including Allecra’s CEO Nicholas Benedict – and the two lead investors. This Series A financing of €15 million euros will support early clinical development of two new antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria.